<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01354782</url>
  </required_header>
  <id_info>
    <org_study_id>RO-2455-101-EC</org_study_id>
    <nct_id>NCT01354782</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study of Single and Repeated Dose of Roflumilast 500 µg , in Healthy Chinese Subjects</brief_title>
  <official_title>An Open, Single Centre, Single and Repeated Dose Study to Investigate the Pharmacokinetic Profile of Roflumilast and Roflumilast N-oxide After Administration of 500 μg Dose of Roflumilast in Healthy Chinese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to assess the pharmacokinetics (PK) of roflumilast and its
      metabolite roflumilast N-oxide after single and repeated oral administrations of roflumilast
      500 μg in healthy Chinese subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the pharmacokinetic profiles after single and repeated dose of roflumilast 500 µg administered to healthy Chinese subjects.</measure>
    <time_frame>Period I: single dose, PK-Investigation over 8 days, Period II: repeated dose for 14 days, PK-Investigation on days 14 and 15</time_frame>
    <description>PK samples at pre-dose, 0.25h, 0.5h, 0.75h, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 16h and 24h, 36h, 48h, 72h, 96h, 120h, 144h and 168h post dose after single dose and at the time points pre-dose, 0.25h, 0.5h, 0.75h, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 16h and 24h after administration of a repeated dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The safety and tolerability of single and repeated dose roflumilast 500 µg will be evaluated in terms of adverse event, ECG, blood pressure, pulse rate, and clinical laboratory tests.</measure>
    <time_frame>During screening, clinical part and final check</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Roflumilast</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(This is a pharmacokinetic study)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Roflumilast</intervention_name>
    <description>Period I: single dose of roflumilast 500 μg orally in the morning.
Period II: repeated dose of roflumilast 500 μg orally in the morning for 14 days.</description>
    <arm_group_label>Roflumilast</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  Healthy male and female (24 male and 8 female) subjects of Chinese ethnic origin, age
             40 years and older.

          -  Assessed as healthy based on a screening examination including medical history,
             physical examination, blood pressure, pulse rate, ECG assessment, and clinical
             laboratory results.

          -  Body weight according to a Body Mass Index (BMI) between 19 and 28 kg/[m²], (both
             inclusive) and a body weight ≥ 50 kg.

          -  Females with childbearing potential who are using medically acceptable and reliable
             method of contraception for the entire study duration, such as tubal ligation,
             hysterectomy, intrauterine device without hormones or post-menopausal females, the
             latter is defined as females who have had no menstrual period for at least 2 years.

        Main Exclusion Criteria:

          -  History or current evidence of clinically relevant allergies or idiosyncrasy to drugs
             or food

          -  History of allergic reactions to roflumilast or any inactive ingredients of the trial
             medication

          -  History or current evidence of any clinically relevant cardiovascular, pulmonary,
             hepatic, renal, gastrointestinal, hematological, endocrinological, metabolic,
             neurological, psychiatric, or other disease (within the last 2 years)

          -  History of malignancy within the past 5 years

          -  Electrocardiogram (ECG) abnormalities of clinical relevance (e.g. QTc according to
             Bazett's formula: QTc &gt; 450 msec (male), QTc &gt; 470 msec (female), PQ ≥ 220 msec)

          -  Blood pressure ≥ 140 mm HG systolic or ≥ 90 mm HG diastolic

          -  Elevated transaminases &gt; 2 x upper Limit of normal range and or increased of the total
             bilirubin &gt; 1.5 upper Limit of normal range

          -  Clinically relevant abnormalities in clinical chemical, hematological or any other
             laboratory variables

          -  Chronic or clinically relevant acute infections

          -  Proneness to orthostatic dysregulation, faintings, or blackouts

          -  Positive results in any of the virology tests of acute or chronic infectious HIV and
             hepatitis A, B, and C virus infections

          -  Positive drug screen

          -  Abuse of alcohol or drugs

          -  Positive β-HCG pregnancy test (female)

          -  Pregnant or lactating females
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AstraZeneca AstraZeneca</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Beijing</city>
        <zip>100032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=4497&amp;filename=RO-2455-101-EC-RDS-2012-04-26.pdf</url>
    <description>RO-2455-101-EC-RDS-2012-04-26.pdf</description>
  </link>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2011</study_first_submitted>
  <study_first_submitted_qc>May 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2011</study_first_posted>
  <last_update_submitted>October 24, 2016</last_update_submitted>
  <last_update_submitted_qc>October 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetic</keyword>
  <keyword>Roflumilast</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

